| Literature DB >> 27458300 |
Wendy van Dorp1, Renée L Mulder1, Leontien C M Kremer1, Melissa M Hudson1, Marry M van den Heuvel-Eibrink1, Marleen H van den Berg1, Jennifer M Levine1, Eline van Dulmen-den Broeder1, Natascia di Iorgi1, Assunta Albanese1, Saro H Armenian1, Smita Bhatia1, Louis S Constine1, Andreas Corrias1, Rebecca Deans1, Uta Dirksen1, Clarisa R Gracia1, Lars Hjorth1, Leah Kroon1, Cornelis B Lambalk1, Wendy Landier1, Gill Levitt1, Alison Leiper1, Lillian Meacham1, Alesandro Mussa1, Sebastian J Neggers1, Kevin C Oeffinger1, Alberto Revelli1, Hanneke M van Santen1, Roderick Skinner1, Andrew Toogood1, William H Wallace1, Riccardo Haupt1.
Abstract
PURPOSE: Female survivors of childhood, adolescent, and young adult (CAYA) cancer who were treated with alkylating agents and/or radiation, with potential exposure of the ovaries, have an increased risk of premature ovarian insufficiency (POI). Clinical practice guidelines can facilitate these survivors' access to optimal treatment of late effects that may improve health and quality of survival; however, surveillance recommendations vary among the existing long-term follow-up guidelines, which impedes the implementation of screening. PATIENTS AND METHODS: The present guideline was developed by using an evidence-based approach and summarizes harmonized POI surveillance recommendations for female survivors of CAYA cancer who were diagnosed at age < 25 years. The recommendations were formulated by an international multidisciplinary panel and graded according to the strength of the evidence and the potential benefit gained from early detection and intervention. The harmonized POI surveillance recommendations were developed by using a transparent process and are intended to facilitate care for survivors of CAYA cancer. RESULTS ANDEntities:
Mesh:
Substances:
Year: 2016 PMID: 27458300 PMCID: PMC5569686 DOI: 10.1200/JCO.2015.64.3288
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544